美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

福佑

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

資料載入中...

總覽公司新聞資訊公告

【信達生物(01801.HK)與羅氏達成新一代DLL3 抗體偶聯藥物的全球獨家許可協議】信達生物(01801.HK)公佈，該公司及其全資附屬公司(包括信達生物製藥(蘇州)有限公司、Fortvita Biologics (Singapore) Pte. Ltd.及福佑泰生物製藥有限公司與F. Hoffmann-La Roche Ltd及 Hoffmann-La Roche Inc.(連同F. Hoffmann-La Roche Ltd統稱為“羅氏”)達成全球獨家合作與許可協議，據此，該集團授予羅氏開發、生產及商業化IBI3009(一款靶向DLL3的新一代抗體偶聯藥物(ADC)候選產品)的全球獨家權益。IBI3009已在澳大利亞、中國和美國獲得臨牀申請(IND)批准，並於2024年12月完成I期臨牀研究首例患者給藥。此次合作旨在為晚期小細胞肺癌 (SCLC)患者提供全新的治療選擇。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/FOYO/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FOYO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FOYO\",,,,,undefined,":{"symbol":"FOYO","market":"US","secType":"STK","nameCN":"福佑","latestPrice":0,"timestamp":0,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"05-09 11:08:09 EDT","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1746820800000},"marketStatusCode":2,"adr":0,"listingDate":1623902400000,"exchange":"NASDAQ","adjPreClose":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FOYO\",,,,,undefined,":{"symbol":"FOYO","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FOYO\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2500095263","title":"【信達生物(01801.HK)與羅氏達成新一代DLL3 抗體偶聯藥物的全球獨家許可協議】信達生物(01801.HK)公佈，該公司及其全資附屬公司(包括信達生物製藥(蘇州)有限公司、Fortvita Biologics (Singapore) Pte. Ltd.及福佑泰生物製藥有限公司與F. Hoffmann-La Roche Ltd及 Hoffmann-La Roche Inc.(連同F. Hoffmann-La Roche Ltd統稱為“羅氏”)達成全球獨家合作與許可協議，據此，該集團授予羅氏開發、生產及商業化IBI3009(一款靶向DLL3的新一代抗體偶聯藥物(ADC)候選產品)的全球獨家權益。IBI3009已在澳大利亞、中國和美國獲得臨牀申請(IND)批准，並於2024年12月完成I期臨牀研究首例患者給藥。此次合作旨在為晚期小細胞肺癌 (SCLC)患者提供全新的治療選擇。","url":"https://stock-news.laohu8.com/highlight/detail?id=2500095263","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500095263?lang=zh_tw&edition=fundamental","pubTime":"2025-01-02 07:28","pubTimestamp":1735774134,"startTime":"0","endTime":"0","summary":"信达生物公布，该公司及其全资附属公司(包括信达生物制药(苏州)有限公司、Fortvita Biologics (Singapore) Pte. Ltd.及福佑泰生物制药有限公司与F. Hoffmann-La Roche Ltd及 Hoffmann-La Roche Inc.(连同F. Hoffmann-La Roche Ltd统称为“罗氏”)达成全球独家合作与许可协议，据此，该集团授予罗氏开发、生产及商业化IBI3009(一款靶向DLL3的新一代抗体偶联药物(ADC)候选产品)的全球独家权益。此次合作旨在为晚期小细胞肺癌 患者提供全新的治疗选择。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/02072847022908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2488822045.USD","01801","BK1583","BK1161","BK4231","BK4080","BK1191","BK1589","FOYO","ADC","BK1574","01477","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FOYO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FOYO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FOYO\",market:\"US\",delay:false,,,undefined,":{}}}